In Brief: FDA considers emergency contraceptive label change, CRN points out FSMA exemptions; NAD refers Maxam claims to FTC
This article was originally published in The Tan Sheet
Executive Summary
FDA considers emergency contraceptive label change; CRN points out FSMA exemptions; NAD refers Maxam claims to FTC; P&G executives retire; nutritional product firms among top direct sellers; Boots recalls store brand products; more In Brief.